NO940597D0 - Isolering, vekst, differensiering og genslöyd på menneskers muskelceller - Google Patents

Isolering, vekst, differensiering og genslöyd på menneskers muskelceller

Info

Publication number
NO940597D0
NO940597D0 NO940597A NO940597A NO940597D0 NO 940597 D0 NO940597 D0 NO 940597D0 NO 940597 A NO940597 A NO 940597A NO 940597 A NO940597 A NO 940597A NO 940597 D0 NO940597 D0 NO 940597D0
Authority
NO
Norway
Prior art keywords
differentiation
isolation
growth
muscle cells
gene silencing
Prior art date
Application number
NO940597A
Other languages
English (en)
Other versions
NO940597L (no
Inventor
Helen M Blau
Simon M Hughes
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of NO940597D0 publication Critical patent/NO940597D0/no
Publication of NO940597L publication Critical patent/NO940597L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO940597A 1991-08-22 1994-02-21 Isolering, vekst, differensiering og genslöyd på menneskers muskelceller NO940597L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/748,348 US5538722A (en) 1989-06-13 1991-08-22 Isolation, growth, differentiation and genetic engineering of human muscle cells
PCT/US1992/006983 WO1993003768A1 (en) 1991-08-22 1992-08-19 Isolation, growth, differentiation and genetic engineering of human muscle cells

Publications (2)

Publication Number Publication Date
NO940597D0 true NO940597D0 (no) 1994-02-21
NO940597L NO940597L (no) 1994-04-19

Family

ID=25009080

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940597A NO940597L (no) 1991-08-22 1994-02-21 Isolering, vekst, differensiering og genslöyd på menneskers muskelceller

Country Status (8)

Country Link
US (1) US5538722A (no)
EP (1) EP0667791A4 (no)
JP (1) JPH07501688A (no)
KR (1) KR100275304B1 (no)
AU (1) AU659673B2 (no)
CA (1) CA2116118A1 (no)
NO (1) NO940597L (no)
WO (1) WO1993003768A1 (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
EP0584339A4 (en) * 1992-03-04 1996-02-28 Jon A Wolff Method of delivering therapeutic substances to the brain
US6432711B1 (en) * 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
EP0737252A1 (en) * 1993-11-10 1996-10-16 Amgen Inc. Gene therapy vector for the treatment of low or defective red blood cell production
US5935849A (en) * 1994-07-20 1999-08-10 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5840576A (en) * 1994-07-20 1998-11-24 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
GB9419048D0 (en) * 1994-09-20 1994-11-09 Watt Diana J Treatment of muscular disorders
US6495364B2 (en) * 1995-05-23 2002-12-17 Neurotech, S.A. Mx-1 conditionally immortalized cells
US5869041A (en) * 1996-01-12 1999-02-09 The Miriam Hospital Delivery of bioactive compounds to an organism
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US6281371B1 (en) 1997-08-13 2001-08-28 Biontex Laboratories Gmbh Lipopolyamines, and the preparation and use thereof
US7115417B1 (en) * 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
CA2330660C (en) 1998-05-01 2012-04-10 University Of Pittsburgh Muscle-derived cell mediated gene delivery for treating muscle-and bone-related injury or dysfunction
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
EP1048725B1 (en) * 1999-04-27 2005-07-06 Transgene S.A. Process for production of mammalian cell lines
EP1048724A1 (en) * 1999-04-27 2000-11-02 Transgene S.A. Human myoblast cell lines and their uses
AU5498800A (en) * 1999-06-25 2001-01-31 Baylor College Of Medicine Stem cells derived from skeletal muscle
JP2003505475A (ja) 1999-07-23 2003-02-12 ダイアクリン インク 筋細胞、及び心臓修復におけるそれらの利用
US20030113301A1 (en) * 1999-07-23 2003-06-19 Albert Edge Muscle cells and their use in cardiac repair
AU5159901A (en) * 2000-04-14 2001-10-30 Univ Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
DE10026480A1 (de) * 2000-05-29 2001-12-13 Augustinus Bader Verfahren zur Herstellung eines empfängerspezifischen Gewebe-Transplantats oder -Implantats
FR2810045B1 (fr) * 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations
WO2002066076A1 (en) * 2001-02-21 2002-08-29 Melbourne Neuromuscular Research Institute A method of treatment and agents useful for same
WO2002067867A2 (en) * 2001-02-23 2002-09-06 The University Of Pittsburgh Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
AU2003220562A1 (en) * 2002-04-01 2003-10-20 Peter K. Law Cellular transplantation for heart regeneration
US20040009155A1 (en) * 2002-07-12 2004-01-15 Maria Palasis Method for sustaining direct cell delivery
WO2004012791A2 (en) * 2002-08-06 2004-02-12 Genvec, Inc. Improved injection system
CN1812800B (zh) * 2003-04-25 2013-01-16 匹兹堡大学 用于促进和增强神经修复和再生的肌肉来源的细胞(mdc)
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US20060263338A1 (en) * 2005-03-04 2006-11-23 Jacoby Douglas B Catheter-based delivery of Skeletal Myoblasts to the Myocardium of Damaged Hearts
JP2008537942A (ja) * 2005-03-31 2008-10-02 マイトジェン， インコーポレイテッド 心疾患のための処置
AU2006244197A1 (en) * 2005-05-09 2006-11-16 Mytogen, Inc. Cellular cardiomyoplasty as supportive therapy in patients with heart disease
WO2008066886A2 (en) * 2006-11-28 2008-06-05 University Of Pittsburgh Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same
US20100158875A1 (en) 2006-12-18 2010-06-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
WO2008076435A1 (en) * 2006-12-18 2008-06-26 University Of Pittsburgh Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
CA2674795C (en) 2007-01-11 2016-08-23 University Of Pittsburgh Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using the same
US20080208164A1 (en) * 2007-02-28 2008-08-28 Innovacell Biotechnologie Gmbh Methods for the treatment of anal incontinence
US20090155221A1 (en) * 2007-05-29 2009-06-18 Thomas Payne Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
BRPI0813352A2 (pt) * 2007-06-15 2014-12-30 Ethicon Inc Composições de fragmento de tecido para o tratamento de incontinência
WO2009045506A2 (en) 2007-10-04 2009-04-09 University Of Pittsburgh- Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
US9199003B2 (en) * 2008-08-18 2015-12-01 University of Pittsburgh—of the Commonwealth System of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
US20100233138A1 (en) * 2008-11-07 2010-09-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vocal Cord Augmentation Utilizing Muscle-Derived Progenitor Compositions, and Treatments Thereof
FR2960783B1 (fr) 2010-06-04 2012-07-27 Ass Pour Les Transferts De Technologies Du Mans Membrane fonctionnalisee pour chambre d'encapsulation de cellules produisant au moins une substance d'interet therapeutique et organe bioartificiel comprenant une telle membrane
US9295696B2 (en) 2012-06-08 2016-03-29 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for restoring or rejuvenating stem/progenitor cell function
US20150247856A1 (en) 2012-09-24 2015-09-03 Innovacell Bioyechnologie Ag Potency assay for skeletal muscle derived cells
EP3095509A1 (en) 2015-05-18 2016-11-23 Defymed Membranes functionalized with heparin for bioartificial organs
CN107920503A (zh) 2015-06-11 2018-04-17 伊利诺伊大学理事会 肌营养不良症嵌合细胞和治疗肌营养不良症的方法
EP3717635A1 (en) 2017-11-28 2020-10-07 The Board of Trustees of the University of Illinois Multi-chimeric cell and therapy for transplantation and treatment of immune deficiencies and genetic disorders
HUE062005T2 (hu) 2017-12-14 2023-09-28 Innovacell Ag Eljárások izomból származó sejtek elõállítására
WO2020238961A1 (en) * 2019-05-29 2020-12-03 Institute Of Zoology, Chinese Academy Of Sciences Compositions and use of engineered myogenic cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443546A (en) * 1980-07-07 1984-04-17 The Beth Israel Hospital Association Process and composition for propagating mammalian cells
US4520821A (en) * 1982-04-30 1985-06-04 The Regents Of The University Of California Growing of long-term biological tissue correction structures in vivo
ATE165516T1 (de) * 1989-03-21 1998-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
JP3244696B2 (ja) * 1989-06-13 2002-01-07 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー ヒト筋肉細胞の単離、増殖および分化
EP0950707B1 (en) * 1989-07-25 2009-02-18 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
AU7312891A (en) * 1990-02-12 1991-09-03 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
CA2128616A1 (en) * 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
CA2133566A1 (en) * 1992-04-10 1993-10-11 Charles P. Emerson, Jr. Transcription control element for increasing gene expression by myoblasts
WO1993024151A1 (en) * 1992-05-29 1993-12-09 The General Hospital Corporation Arterial introduction of myoblasts

Also Published As

Publication number Publication date
US5538722A (en) 1996-07-23
AU2515792A (en) 1993-03-16
JPH07501688A (ja) 1995-02-23
NO940597L (no) 1994-04-19
WO1993003768A1 (en) 1993-03-04
AU659673B2 (en) 1995-05-25
KR100275304B1 (ko) 2000-12-15
EP0667791A4 (en) 1996-05-08
EP0667791A1 (en) 1995-08-23
CA2116118A1 (en) 1993-03-04

Similar Documents

Publication Publication Date Title
NO940597D0 (no) Isolering, vekst, differensiering og genslöyd på menneskers muskelceller
NO880193D0 (no) Vevveksthjelpemiddel og fremstilling derav.
NO933434D0 (no) Piperidinderivater, deres fremstilling og anvendelse
DK476089A (da) Terapeutisk aktive forbindelser og deres fremstilling
DK157488D0 (da) Substituerede triazolinoner, deres fremstilling og anvendelse
NO922275D0 (no) Aryletere, deres fremstilling og fremgangsmaate for behandling
EP0871707A4 (en) MANIPULATION OF VEGETABLE CELL AND TISSUE CULTURES
NO883271D0 (no) Vevfaktorinhibitor og isolering derav.
NO931186L (no) Terapeutisk aktive imidazolderivater, fremgangsmaate for deres fremstilling og anvendelse derav
DK0670890T4 (da) Bioreaktor med immobiliserede mælkesyrebakterier og anvendelsen deraf
DK595388A (da) Benzopyranderivater, deres fremstilling og anvendelse
DK62589D0 (da) Kloning og ekspression af human vaekstfaktor
DK193088A (da) 2-acylpyrrolidin-derivater, deres fremstilling og anvendelse
NO933435D0 (no) Piperidinderivater, deres fremstilling og anvendelse
DK278188A (da) Thiazolidin-4-on-derivater, deres fremstilling og anvendelse
DK35588A (da) Hoejniveau-ekspression i e. coli af oploeseligt, modent humant interleukin-1beta og derivater med aendret biologisk virkning
DK8589D0 (da) Pyrazol- og indazolpyridinaminer, deres fremstilling og anvendelse
DK360189D0 (da) S-adenosyl-methionin-decarboxylase-inhibitorer, deres fremstilling og anvendelse
DK189488A (da) Imidazothiadiazinderivater, deres fremstilling og anvendelse
GB9125052D0 (en) Culture of bone cells
DK223288A (da) Benzensulfornamid-derivater, deres fremstilling og anvendelse
AU6125496A (en) Human growth factors, nucleotide sequence encoding growth factors, and methods of use thereof
DK412188A (da) Benzothiazinon-derivater, deres fremstilling og anvendelse
NO892506L (no) Kloning og ekspresjon av human vevsfaktor.
DK361388D0 (da) Cephemderivater, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application